McKesson Is Down 7% Over 166 Days. What History Says Now

McKesson's 166-Day Drawdown: What History Says About Its Recovery

McKesson Corporation (MCK) is now down 7% from its all-time high as of September 2, 2026, having just exited the yellow zone after exactly 166 days in drawdown. The Drawdown Severity Score™ has improved to 1.6, which represents a Slightly Elevated level. In 44 comparable historical drops of 5% or more, the stock spent an average of 219 days recovering.

To understand this transition, we must examine how other large-cap stocks recover from similar pullbacks. Historically, when defensive equities exit a yellow risk zone, it signals that selling pressure has reached a point of exhaustion. Other major healthcare distributors have followed a similar trajectory, where a recovery in the severity score to a Slightly Elevated level of 1.6 precedes a period of price consolidation before the stock attempts to reclaim its previous highs.

The Numbers: Severity Improvement, Price Change, and Timeline

As of September 2, 2026, McKesson trades at $924.78, representing a -7.1% drawdown from its all-time high of $995.69. This decline has persisted for 166 days, during which the stock spent considerable time in the yellow zone, indicating moderate risk. The recent upward price movement has improved the Drawdown Severity Score™ to 1.6, categorizing the stock's current drawdown as Slightly Elevated.

This transition to the green zone indicates that the stock is stabilizing, though it remains below its peak. Investors tracking the recovery timeline should note how the current pullback compares to the stock's historical averages.

Peer Comparison: How Similar Large-Cap Recoveries Play Out

When large-cap healthcare stocks recover from the yellow zone to a Slightly Elevated 1.6 score in the green zone, it often indicates a broader market stabilization. For example, peer companies in the medical distribution space, such as Cardinal Health (CAH), have historically exhibited similar patterns. When these stocks experience pullbacks in the -5% to -10% range and subsequently cross back into the green zone, the transition is typically marked by a reduction in daily trading volatility.

Our data shows that a return to a Slightly Elevated severity score of 1.6 suggests that institutional accumulation is beginning to offset retail panic. Large-cap distributors are highly sensitive to broader supply chain dynamics and healthcare spending cycles. When these macro pressures ease, these stocks tend to recover in a structured, multi-month pattern rather than making immediate, volatile moves back to all-time highs.

Historical Pattern: Analyzing McKesson's 203 Drawdown Events

To evaluate the likelihood of a full recovery, we must analyze McKesson's historical performance. Over its trading history, we have recorded a total of 203 historical drawdown events for the stock. The average maximum drawdown across all of these recorded events is -4.0%, with an average drawdown duration of 54 days.

The current drawdown of -7.1% is deeper and has lasted significantly longer than the historical average of 54 days. However, when we filter for more severe pullbacks, our data shows that McKesson has experienced a drop of 5% or more from its peak exactly 44 times.

For these 44 comparable drops of 5% or more, the average duration of the drawdown was 219 days. Comparing the current 166-day timeline to this historical benchmark of 219 days shows that the current recovery is progressing slightly ahead of the historical average. This historical context suggests that while a 166-day drawdown may seem prolonged, it is well within the normal historical bounds for pullbacks of this depth.

Valuation Context: Price Drawdown vs. Historical Multiples

To put this price drawdown into broader historical context, we can look at McKesson's valuation metrics as of 2026-08-31. Despite the -7.1% drawdown from its all-time high, the stock's valuation multiples remain high relative to its own history. The Price-to-Sales (P/S) ratio stands at 0.26, which is in the 89th percentile of its own daily P/S record since 2006-08-31, well above its historical median of 0.18. Similarly, the EV-to-EBITDA (EV/EBITDA) ratio is 15.1, placing it in the 83rd percentile of its own daily record since 2006-08-31, compared to a historical median of 9.8. This indicates that while the price has declined, the valuation multiples remain elevated relative to the company's long-term historical trading range.

Fundamental Drivers: Strategic Acquisitions and Market Catalysts

Several recent fundamental developments have influenced McKesson's stock price movement and contributed to its recovery toward the green zone. According to a report by TradingKey, McKesson stock moved up by 3.13% on September 1, 2026, driven by strong market interest and positive sector momentum. This upward movement helped lift the stock out of the yellow zone and improved its overall technical posture.

Additionally, business expansion efforts have supported investor sentiment. As reported by Business Wire, McKesson recently signed an agreement to acquire Precision Medicine Group, LLC, a move aimed at expanding its specialized pharmaceutical and oncology capabilities. This strategic acquisition has provided a fundamental catalyst, helping to stabilize the stock's price action.

Market analysts are also closely watching the company's trajectory. A recent Yahoo Finance report discussing the McKesson stock outlook highlighted a mix of bullish and bearish perspectives on Wall Street, with many analysts focusing on the company's robust role as a healthcare giant and its potential for long-term growth.

Remaining Distance: The Path to Reclaiming All-Time Highs

As of September 2, 2026, McKesson trades at $924.78, leaving a remaining distance of $70.91 to reach its all-time high of $995.69. This represents a required gain of 7.67% from the current price level. While the improvement of the Drawdown Severity Score™ to 1.6 indicates that the immediate downward pressure has eased, the stock still has ground to cover.

Historically, once the stock stabilizes in the green zone, the remaining recovery period can vary depending on macroeconomic conditions. Investors tracking McKesson should monitor whether the stock can maintain its position in this Slightly Elevated range or if macroeconomic factors will push it back into a deeper drawdown. The transition out of the yellow zone is a positive technical sign, but the elevated valuation percentiles suggest that the market continues to price in high expectations for the healthcare distributor.